Maximizing anticholinergic therapy for overactive bladder: Has the ceiling been reached?

BJU International

Volumn 99, Issue SUPPL. 3, 2007, Pages 8-12

  MacDiarmid, Scott A ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b The Urology Center   (United States)

Author keywords

Anticholinergic agents; Dry mouth; N desethyloxybutynin; Overactive bladder; Oxybutynin; Oxybutynin transdermal delivery system; Tolterodine; Urinary incontinence

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

APPLICATION SITE ERYTHEMA; BEHAVIOR THERAPY; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG FORMULATION; HEADACHE; HUMAN; LONG TERM CARE; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; TRANSDERMAL PATCH; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; HUMANS; LONG-TERM CARE; MIDDLE AGED; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 34247271263     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06881.x     Document Type: Review

References (24)

1. Ko Y, Lin SJ, Salmon JW, Bron MS. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 2005;11 (Suppl.): S103-11
2. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-4
3. Burgio KL, Goode PS, Locher JL et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002; 288: 2293-9
4. U.S. National Institutes of Health resources page. Using behavioral therapy in combination with darifenacin for symptoms of overactive bladder. ClinicalTrials.gov Website, Available at: http://www.clinicaltrials. gov/ct/show/NCT00127270. Accessed March 2007
5. Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology 1999; 54: 420-3
6. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybuytnin Study Group. J Urol 1999; 161: 1809-12
7. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000; 95: 718-21
8. Dmochowski RR, Davila GW, Zinner NR et al.; for The Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-6
9. Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005; 23: 263-70
10. Corcos J, Casey R, Patrick A et al.; Uromax Study Group. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2006; 97: 520-7
11. MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol 2005; 174: 1301-5
12. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 67: 275-80
13. 3-selective receptor antagonist. BJU Int 2005; 95: 580-6
14. Chapple CR, Martinez-Garcia R, Selvaggi L et al.; for the STAR Study Group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70
15. Bennett N, O'Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004; 171: 749-51
16. O'Leary M, Erickson JR, Smith CP, McDermott C, Horton J, Chancellor MB. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003; 26: 159-62
17. Ouslander JG, Ya-chen TS, Malone-Lee J, Luber K. Overactive bladder: special considerations in the geriatric population. Am J Manag Care 2000; 6 (Suppl.): S599-606
18. Mullins CD, Subak LL. New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs 2005. Am J Manag Care 2005; 11 (Suppl.): S101-2
19. Nitz NM, Jumadilova Z, Darkow T, Frytak JR, Bavendam T. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. Am J Manag Care 2005; 11 (Suppl.): S130-9
20. Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med 2006; 119 (Suppl. 1): 29-36
21. Sand PK, Lucente VR, Parker RL, Goldberg RP, Dahl NV. Impact of transdermal oxybutynin on depression symptoms in patients with overactive bladder. Results of the MATRIX study. Obstet Gynecol 2006; 107: 76S
22. Davila GW, Sand PK, Gonick CW, Parker RL, Dahl NV. Impact of transdermal oxybutynin on nocturia and related symptoms in overactive bladder. Results from MATRIX study. Obstet Gynecol 2006; 107: 76S
23. Cafiero MR. Comparison of depression symptoms in patients with OAB before and after treatment with transdermal oxybutynin: results from the MATRIX Study. Oral Paper Presented at the 38th Annual Conference of the Wound Ostomy and Continence Nurses (WOCN) Society; June 24-28, 2006; Minneapolis, Minn. 106. Available at: http://Wocn.Confex.Com/Wocn/2006annual/techprogram/ P1874.HTM. Accessed 21 March 2007
24. Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78: 696-702